Nasdaq rxrx.

Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...

Nasdaq rxrx. Things To Know About Nasdaq rxrx.

Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share volumes, and more. Make informed investments with Nasdaq.2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two ...

Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 320.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The institutional investor owned 3,523,124 shares of the company's stock …

The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by TD Cowen on Friday, January 26, 2024.The analyst firm set a price target for 0.00 expecting RXRX to fall to ...Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.Recursion Pharmaceuticals Insider Sold Shares Worth $117,180, According to a Recent SEC Filing. Nov. 17. MT. Recursion Pharmaceuticals Insider Sold Shares Worth $340,929, According to a Recent SEC Filing. Nov. 17. MT. JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating.Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...

An analysis of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stock in terms of its daily trading volume indicates that the 3-month average is 4.10 million. However, this figure increases on the past 10-day timeline to an average of 4.76 million. Current records show that the company has 183.21M in outstanding shares.

RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals ( RXRX -2.02%), and GE Healthcare Technologies ( GEHC -2.82%) are already using AI to boost ...SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6 ...

REC-2282 is developed for the treatment of neurofibromatosis type 2. paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart.Jan 17, 2024 · Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media. Current. 2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...Nov 16, 2023 · JuSun/iStock via Getty Images. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline.That's because it has been advancing two ... SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to …

Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...For a biotech like Recursion Pharmaceuticals (RXRX-1.25%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...

Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share volumes, and more. Make informed investments with Nasdaq.

6 days ago · PTC Therapeutics (NASDAQ:PTCT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better investment?We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...December 29, 2023. Shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX - Get Free Report) dropped 1.9% on Friday following insider selling activity. The stock traded as low as $10.41 and last traded at $10.41. Approximately 154,367 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 3,473,452 …The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on January 17, 2024.The analyst firm set a price target for $15.00 expecting RXRX to rise to within ... Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock positioned to win no matter which companies capture the largest market share.TWST creates synthetic DNA, which is critical to early ...Jan 4, 2024 · Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ...SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to …Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …

GuruFocus Research January 25, 2024 at 8:52 PM · 2 min read Director Blake Borgeson of Recursion Pharmaceuticals Inc ( NASDAQ:RXRX) has sold 20,054 shares …Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... Instagram:https://instagram. brannen kennedy funeral home obituariesapplebeepercent27s grill and bar huntington menukxosul.suspectedlululemon scuba oversized funnel neck full zip Shares of Recursion Pharmaceuticals ( RXRX -4.40%) sank 17.7% lower as of the market close on Wednesday. The decline came after the company provided its third-quarter update Wednesday morning ... n 1 grand prix battle catslast year See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. manana como va a estar el clima November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...